

Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Firdapse (amifampridine phosphate) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 6 months; Continuation- 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Firdapse (amifampridine phosphate).** Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: <u>1-866-331-2104</u>]. If you have any questions or concerns, please call <u>1-866-331-2103</u>. **Requests will not be considered unless this form is complete.**

KP-MAS Formulary can be found at: Pharmacy | Community Provider Portal | Kaiser Permanente

1 – Patient Information			
Patient Name:	Kaiser Medical ID#:	Date of Birth:	
2 – Provider Information			
Is the prescriber a neurologist or in consultation with a neurologist? □ No □ Yes			
If consulted with a specialist, specialist name and specialty:			
Provider Name:	Specialty:	Provider NPI:	
Provider Address:			
Provider Phone #:	Provider Fax #:		
3 – Pharmacy Information			
Pharmacy Name:	Pharmacy NPI:		
Pharmacy Phone #	Pharmacy Fax #:		
4 – Drug Therapy Requested			
Drug 1: Name/Strength/Formulation: _			
Sig:			
5– Diagnosis/Clinical Criteria			
1. Is this request for initial or continu	· · · · · · · · · · · · · · · · · · ·		
☐ Initial therapy ☐ ☐	Continuing therapy, state start date:		
2. Indicate the patient's diagnosis for	the requested medication:		

	nical Criteria: Documented confirmed diagnosis of Lambert-Eaton metabolic syndrome (LEMS) based on clinical, serologic, and electrodiagnostic exam		
	□ No □ Yes		
2.	AND patient is ≥18 years,		
	□ No □ Yes		
3.	AND patient is ambulatory,		
	□ No □ Yes		
4.	 AND patient does NOT have a history of seizures or active brain metastases, □ No □ Yes 		
5.	AND forced vital capacity (%FVC) ≥60% □ No □ Yes		
For continuation of therapy, please respond to <u>additional questions</u> below:			
1.	ECG, renal function and liver function testing completed annually		
	□ No □ Yes		
2.	AND member is still ambulatory		
	□ No □ Yes		
3.	AND member has NOT developed epileptic seizures		
	□ No □ Yes		
4.	AND member is adherent to therapy		
	□ No □ Yes		
5.	AND member has documented improvement from baseline		
	□ No □ Yes		
	7 Dunwidou Sign Off		
Δd	7 – Provider Sign-Off ditional Information –		
	Please submit chart notes/medical records for the patient that are applicable to this request.		
2.			
	information that should be taken into consideration for the requested medication:		
I certify that the information provided is accurate. Supporting documentation is available for State audits.			
	ovider Signature: Date:		
Ple	ase Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is		

private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility